University of California San Francisco

Francis Yao - 144
Francis
Yao
MD

Professor of Clinical Medicine and Surgery,
Departments of Medicine and Surgery
Medical Director, Liver Transplant Service
Director for Community Liaison, Liver Transplant Service

Address

400 Parnassus Avenue, #A745
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-514-0250
Fax: 415-476-0659

Biography

Dr. Francis Yao is a gastroenterologist who serves as medical director of the UCSF Liver Transplant Program. He also directs the UCSF Liver Transplant Outreach and Community Liaison Program.

In his research, Yao is interested in liver cancer treatment, particularly as related to liver transplants. He has contributed to important publications in this area. His other research interests include hepatitis B infection and outcomes for patients undergoing liver transplantation.

Education

Institution Degree Dept or School End Date
Stanford Hospital and Clinics Fellowship Gastroenterology 1993
Stanford Hospital and Clinics Residency Internal Medicine 1990
Albert Einstein College of Medicine 1987

Board Certifications

1995 American Board of Internal Medicine - ABIM 147033 (Re-certification 2008)
1997 American Board of Gastroenterology - ABIM 147033 

Clinical Expertise

Cirrhosis
Esophageal Cancer
Liver Transplantation
Primary Sclerosing Cholangitis
Hepatitis B
Hepatitis C
Hepatocellular Carcinoma (Liver Cancer)
Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Steatohepatitis (NASH)
Live Donor Liver Transplantation
Gastric (Stomach) Cancer

Program Affiliations

UCSF Helen Diller Family Comprehensive Cancer Center

UCSF Liver Transplant Program

UCSF Liver Center

In the News

New AASLD Video Showcases UCSF Liver Transplant Program
December, 20, 2014 | UCSF Transplant Surgery
The Nathan Bass UCSF Liver Transplant Conference Set for November 16-17th, 2012 in Napa, CA
September, 27, 2012 | UCSF Transplant Surgery

Research Interests

Liver Injury and Repair

Liver transplantation outcomes including expanded criteria liver transplants

Loco-regional therapy for hepatocellular carcinoma

Hepatitis in Asians

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 120
  1. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma.
    Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP| | PubMed
  2. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
    Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U| | PubMed
  3. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?
    Yao FY, Roberts JP| | PubMed
  4. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
    Yao FY, Bass NM, Ascher NL, Roberts JP| | PubMed
  5. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores.
    Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP| | PubMed
  6. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation.
    Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY| | PubMed
  7. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
    Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, Ascher NL, Roberts JP| | PubMed
  8. Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis.
    Yao FY| | PubMed
  9. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.
    Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP| | PubMed
  10. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.
    Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP| | PubMed
120
View all 120 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 120
  1. Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study.
    Xu E, Tabrizian P, Gutierrez J, Hoteit M, Ghaziani T, Zhou K, Parikh N, Ajmera V, Aby E, Shui A, Marino R, Martin A, Wong C, Kao K, Dave S, Florman S, Yao F, Mehta N| | PubMed
  2. Enhancing the prognostic accuracy of the RETREAT score with AFP-L3 and DCP tumor markers.
    Norman JS, Li PJ, Kotwani P, Yao FY, Pham S, Gamez J, Mehta N| | PubMed
  3. Real-World Management of Hepatocellular Carcinoma: Selected Case Presentations Highlighting the Dilemmas of Surveillance.
    Zheng E, Yao F| | PubMed
  4. Alcohol and Hepatocellular Carcinoma.
    Ha NB, Yao F| | PubMed
  5. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
    Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N| | PubMed
  6. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.
    Natarajan B, Tabrizian P, Hoteit M, Frenette C, Parikh N, Ghaziani T, Dhanasekaran R, Guy J, Shui A, Florman S, Yao FY, Mehta N| | PubMed
  7. Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies.
    Mehta N, Kelley RK, Yao FY| | PubMed
  8. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study.
    Mehta N, Kotwani P, Norman J, Shui A, Li PJ, Saxena V, Chan W, Yao FY| | PubMed
  9. Alpha-fetoprotein slope over 7.5 ng/ml over 3 months before liver transplantation for hepatocellular carcinoma predicts recurrence even after controlling for alpha-fetoprotein at liver transplantation.
    Giard JM, Dodge JL, Yao FY, Mehta N| | PubMed
  10. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
    Huang AC, Dodge JL, Yao FY, Mehta N| | PubMed
  11. National experience with living donor liver transplantation for hepatocellular carcinoma.
    Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N| | PubMed
  12. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma.
    Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N| | PubMed
  13. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N| | PubMed
  14. Review of Liver Transplantation in Patients With Hepatocellular Carcinoma.
    Yao F| | PubMed
  15. Sex-based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC| | PubMed
  16. Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium-90 Radioembolization: Pipe Dream or Reality?
    Mehta N, Yao FY| | PubMed
  17. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY| | PubMed
  18. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma.
    Harding-Theobald E, Yao FYK, Mehta N| | PubMed
  19. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma.
    Lokken RP, Kerlan RK, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N| | PubMed
  20. Disseminated Legionella micdadei infection in a liver transplant patient presenting as pulmonary nodules and a laryngeal lesion.
    Bond AR, Bainbridge E, Doernberg SB, Babik JM, Miller S, Khanafshar E, Henry T, David A, Russell M, Brandman D, Sherman CB, Yao F, Fung M| | PubMed
  21. DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study.
    Kotwani P, Chan W, Yao F, Mehta N| | PubMed
  22. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma.
    Yao FY, Fidelman N, Mehta N| | PubMed
  23. Reply.
    Mehta N, Yao FY| | PubMed
  24. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N, Dodge JL, Roberts JP, Yao FY| | PubMed
  25. CON: Portal Vein Thrombosis Does Not Impact Liver Transplantation Outcomes.
    Sherman C, Syed S, Gardner J, Yao FY| | PubMed
  26. COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions.
    Syed SM, Gardner J, Roll G, Webber A, Mehta N, Shoji J, Adelmann D, Niemann C, Braun HJ, Mello A, Yao F, Posselt A, Kang SM, Hirose R, Roberts J, Feng S, Ascher N, Stock P, Freise C| | PubMed
  27. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.
    Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG| | PubMed
  28. Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival.
    Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM| | PubMed
  29. Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma.
    Weinfurtner K, Dodge JL, Yao FYK, Mehta N| | PubMed
  30. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.
    Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N| | PubMed
  31. Bacchus Listed for a Liver Transplant: Comment.
    Kronish K, Freise CE, Yao FY| | PubMed
  32. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
    Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A| | PubMed
  33. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
    Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N| | PubMed
  34. Liver transplantation for hepatocellular carcinoma: Management after the transplant.
    Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY| | PubMed
  35. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N, Dodge JL, Grab JD, Yao FY| | PubMed
  36. REPLY.
    Mehta N, Dodge JL, Yao FY| | PubMed
  37. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.
    Gutin L, Yao F, Dodge JL, Grab J, Mehta N| | PubMed
  38. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve.
    Fidelman N, Johanson C, Kohi MP, Kolli KP, Kohlbrenner RM, Lehrman ED, Taylor AG, Kelley RK, Yao FY, Roberts JP, Kerlan RK| | PubMed
  39. Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates.
    DesJardin JT, Manicardi M, Svetlichnaya Y, Kolaitis NA, Papolos AI, Selby VN, Zier LS, Klein L, Aras MA, Yao FY, Roberts JP, De Marco T| | PubMed
  40. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
    Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F| | PubMed
  41. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
    Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | PubMed
  42. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?
    Mehta N, Yao FY| | PubMed
  43. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
  44. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria.
    Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N| | PubMed
  45. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
    Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM| | PubMed
  46. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead.
    Mehta N, Monto A, Yao FY| | PubMed
  47. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.
    Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G| | PubMed
  48. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | PubMed
  49. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma.
    Samoylova ML, Mehta N, Roberts JP, Yao FY| | PubMed
  50. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
    Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA| | PubMed
  51. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY| | PubMed
  52. History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist.
    Kotwani P, Saxena V, Dodge JL, Roberts J, Yao F, Hameed B| | PubMed
  53. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)?
    Mehta N, Yao FY| | PubMed
  54. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
    Mehta N, Dodge JL, Roberts JP, Yao FY| | PubMed
  55. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.
    Mehta N, Yao FY| | PubMed
  56. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
    Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY| | PubMed
  57. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
  58. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
    Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY| | PubMed
  59. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
    Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D| | PubMed
  60. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY| | PubMed
  61. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)?
    Mehta N, Yao FY| | PubMed
  62. Reply.
    Mehta N, Yao FY| | PubMed
  63. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant.
    Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N| | PubMed
  64. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story?
    Mehta N, Roberts JP, Yao FY| | PubMed
  65. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan.
    Mehta N, Yao FY| | PubMed
  66. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition?
    Mehta N, Yao FY| | PubMed
  67. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
    Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY| | PubMed
  68. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy?
    Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY| | PubMed
  69. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?
    Yao FY, Fidelman N| | PubMed
  70. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.
    Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY| | PubMed
  71. Implications of discordant findings between hepatic angiography and cross-sectional imaging in transplant candidates with hepatocellular carcinoma.
    Young K, Fidelman N, Yao FY, Hills NK, Kohi MP, Kolli KP, Taylor AG, Kerlan RK| | PubMed
  72. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
    Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW| | PubMed
  73. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
    Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP| | PubMed
  74. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation.
    Vagefi PA, Dodge JL, Yao FY, Roberts JP| | PubMed
  75. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.
    Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP| | PubMed
  76. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization.
    Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N| | PubMed
  77. Response to letter to the editors.
    Yao FY, Hameed B, Mehta N, Roberts JP| | PubMed
  78. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes.
    Sharpton SR, Feng S, Hameed B, Yao F, Lai JC| | PubMed
  79. Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience.
    Flemming JA, Vagefi PA, Freise CE, Yao FY, Terrault NA| | PubMed
  80. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY| | PubMed
  81. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.
    Samoylova ML, Dodge JL, Yao FY, Roberts JP| | PubMed
  82. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | PubMed
  83. Conundrum of treatment for early-stage hepatocellular carcinoma: radiofrequency ablation instead of liver transplantation as the first-line treatment?
    Yao FY| | PubMed
  84. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY| | PubMed
  85. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database.
    Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP| | PubMed
  86. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation.
    Mehta N, Yao FY| | PubMed
  87. Reply: To PMID 23333661.
    Yao F, Mehta N| | PubMed
  88. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.
    Mehta N, Fidelman N, Sarkar M, Yao FY| | PubMed
  89. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
    Garwood ER, Fidelman N, Hoch SE, Kerlan RK, Yao FY| | PubMed
  90. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
    Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA| | PubMed
  91. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation.
    Kwan SW, Fidelman N, Ma E, Kerlan RK, Yao FY| | PubMed
  92. Multidisciplinary management of hepatocellular carcinoma.
    Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N| | PubMed
  93. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?
    Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M| | PubMed
  94. Do preoperative inflammatory markers impact on outcome after liver transplantation for hepatocellular carcinoma?
    Sapisochin G, Yao FY, Roberts JP| | PubMed
  95. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma.
    Sapisochin G, Fidelman N, Roberts JP, Yao FY| | PubMed
  96. Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation.
    Ladabaum U, Cheng SL, Yao FY, Roberts JP| | PubMed
  97. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation.
    Roberts JP, Venook A, Kerlan R, Yao F| | PubMed
  98. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.
    Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP| | PubMed
  99. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria.
    Yao FY| | PubMed
  100. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation.
    Hanje AJ, Yao FY| | PubMed
  101. Liver transplantation for hepatocellular carcinoma.
    Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, Bhoori S, Lee SG| | PubMed
  102. Liver transplantation at UCSF--a 20-year experience.
    Hirose R, Yao F, Stock P, Roberts J, Ascher N| | PubMed
  103. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma.
    Yao FY| | PubMed
  104. Liver transplantation for hepatocellular carcinoma: the hepatitis C quandary.
    Yao FY| | PubMed
  105. Should surveillance for hepatocellular carcinoma be increased in patients with cirrhosis and small liver nodules?
    Yao FY| | PubMed
  106. De novo malignancies following liver transplantation: a case-control study with long-term follow-up.
    Yao FY, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG| | PubMed
  107. Expanded criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation--yes.
    Yao FY| | PubMed
  108. Selection criteria for liver transplantation in patients with hepatocellular carcinoma: beyond tumor size and number?
    Yao FY| | PubMed
  109. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.
    Yao FY, Hirose R, LaBerge JM, Davern TJ, Bass NM, Kerlan RK, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP| | PubMed
  110. High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome.
    Cruz E, Ascher NL, Roberts JP, Bass NM, Yao FY| | PubMed
  111. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma.
    Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP| | PubMed
  112. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
    Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U| | PubMed
  113. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?
    Yao FY, Roberts JP| | PubMed
  114. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
    Yao FY, Bass NM, Ascher NL, Roberts JP| | PubMed
  115. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores.
    Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP| | PubMed
  116. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation.
    Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY| | PubMed
  117. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
    Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, Ascher NL, Roberts JP| | PubMed
  118. Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis.
    Yao FY| | PubMed
  119. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.
    Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP| | PubMed
  120. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.
    Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP| | PubMed